↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Träfflista för sökning "WFRF:(Knowles D) srt2:(2015-2019)"

Search: WFRF:(Knowles D) > (2015-2019)

Result 1-10 of 51

Sort/group result

Sort by: Hits per page:

Enumeration	Reference	Cover	Find
1.	Corbalan, R, et al. (author) Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation: A Report From the GARFIELD-AF Registry 2019 In: JAMA cardiology. - : American Medical Association (AMA). - 2380-6591 .- 2380-6583. ; 4:6, s. 526-548 Journal article (peer-reviewed)
2.	Szarek, M, et al. (author) Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial 2019 In: Circulation. Cardiovascular quality and outcomes. - : Ovid Technologies (Wolters Kluwer Health). - 1941-7705 .- 1941-7713. ; 12:11, s. e005858- Journal article (peer-reviewed)
3.	Jukema, JW, et al. (author) Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial 2019 In: Journal of the American College of Cardiology. - : Elsevier BV. - 1558-3597 .- 0735-1097. ; 74:9, s. 1167-1176 Journal article (peer-reviewed)
4.	Ray, KK, et al. (author) Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial 2019 In: The lancet. Diabetes & endocrinology. - 2213-8595 .- 2213-8587. ; 7:8, s. 618-628 Journal article (peer-reviewed)
5.	Roe, MT, et al. (author) Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes 2019 In: Circulation. - : Ovid Technologies (Wolters Kluwer Health). - 1524-4539 .- 0009-7322. ; 140:19, s. 1578-1589 Journal article (peer-reviewed)
6.	Szarek, M, et al. (author) Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial 2019 In: Journal of the American College of Cardiology. - : Elsevier BV. - 1558-3597 .- 0735-1097. ; 73:4, s. 387-396 Journal article (peer-reviewed)
7.	Goodman, SG, et al. (author) Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery 2019 In: Journal of the American College of Cardiology. - : Elsevier BV. - 1558-3597 .- 0735-1097. ; 74:9, s. 1177-1186 Journal article (peer-reviewed)
8.	Schwartz, GG, et al. (author) Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome 2018 In: The New England journal of medicine. - : MASSACHUSETTS MEDICAL SOC. - 1533-4406 .- 0028-4793. ; 379:22, s. 2097-2107 Journal article (peer-reviewed)
9.	Davies, G., et al. (author) Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function 2018 In: Nature Communications. - : Nature Publishing Group. - 2041-1723. ; 9:1 Journal article (peer-reviewed)abstract General cognitive function is a prominent and relatively stable human trait that is associated with many important life outcomes. We combine cognitive and genetic data from the CHARGE and COGENT consortia, and UK Biobank (total N = 300,486; age 16-102) and find 148 genome-wide significant independent loci (P < 5 × 10-8) associated with general cognitive function. Within the novel genetic loci are variants associated with neurodegenerative and neurodevelopmental disorders, physical and psychiatric illnesses, and brain structure. Gene-based analyses find 709 genes associated with general cognitive function. Expression levels across the cortex are associated with general cognitive function. Using polygenic scores, up to 4.3% of variance in general cognitive function is predicted in independent samples. We detect significant genetic overlap between general cognitive function, reaction time, and many health variables including eyesight, hypertension, and longevity. In conclusion we identify novel genetic loci and pathways contributing to the heritability of general cognitive function.
10.	Menden, MP, et al. (author) Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen 2019 In: Nature communications. - : Springer Science and Business Media LLC. - 2041-1723. ; 10:1, s. 2674- Journal article (peer-reviewed)abstract The effectiveness of most cancer targeted therapies is short-lived. Tumors often develop resistance that might be overcome with drug combinations. However, the number of possible combinations is vast, necessitating data-driven approaches to find optimal patient-specific treatments. Here we report AstraZeneca’s large drug combination dataset, consisting of 11,576 experiments from 910 combinations across 85 molecularly characterized cancer cell lines, and results of a DREAM Challenge to evaluate computational strategies for predicting synergistic drug pairs and biomarkers. 160 teams participated to provide a comprehensive methodological development and benchmarking. Winning methods incorporate prior knowledge of drug-target interactions. Synergy is predicted with an accuracy matching biological replicates for >60% of combinations. However, 20% of drug combinations are poorly predicted by all methods. Genomic rationale for synergy predictions are identified, including ADAM17 inhibitor antagonism when combined with PIK3CB/D inhibition contrasting to synergy when combined with other PI3K-pathway inhibitors in PIK3CA mutant cells.

Skapa referenser, mejla, bekava och länka

Permalink

Result 1-10 of 51

Refine your search

Type of publication: journal article (50); conference paper (1)

Type of content: peer-reviewed (47); other academic/artistic (4)

Author/Editor: Ripke, S (20); Knowles, JA (20); Gill, M. (20); Sullivan, PF (18); Craddock, N (18); McIntosh, AM (17); show more...; Smoller, JW (17); Wray, NR (17); Degenhardt, F (17); Schulze, TG (17); Herms, S. (17); Strohmaier, J (17); Frank, J (17); Witt, SH (17); Breen, G (16); Werge, T (16); Mattheisen, M (16); Cichon, S (16); Montgomery, GW (16); Muller-Myhsok, B (16); Nothen, MM (16); Rietschel, M (16); Martin, NG (16); Kendler, KS (16); O'Donovan, MC (16); Hoffmann, P (15); Medland, SE (15); Levinson, DF (15); Mors, O (15); Esko, T (15); Metspalu, A (15); MacIntyre, DJ (15); Blackwood, DHR (15); Escott-Price, V (15); Steinberg, S (14); Mortensen, PB (14); Webb, BT (14); Lucae, S (14); Lewis, CM (14); Agerbo, E (14); Hougaard, DM (14); Shi, JX (14); Stefansson, K (14); Perlis, RH (14); Treutlein, J (14); Forstner, AJ (14); Stefansson, H. (14); Visscher, PM (14); Bacanu, SA (14); Bigdeli, TB (14); show less...

University: Karolinska Institutet (44); Uppsala University (12); Umeå University (10); University of Gothenburg (7); Lund University (4); Stockholm University (3); show more...; Royal Institute of Technology (2); Linköping University (2); Jönköping University (2); Chalmers University of Technology (1); show less...

Language: English (51)

Research subject (UKÄ/SCB): Medical and Health Sciences (29); Natural sciences (7); Engineering and Technology (1); Social Sciences (1); Humanities (1)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - National Library Systems
LIBRIS.kb.se

pil uppåt

Close

Copy and save the link in order to return to this view